EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.

Khoubai FZ, Calovoulos A, Guillorit H, Carrillo-Reixach J, Del Rio-Alvarez A, Klein P, Coma MS, Avignon C, Rousseau B, Mora Charrot L, Fedou S, Dupuy JW, Royo L, Domingo-Sàbat M, Thézé N, Siegfried G, Khatib AM, Cairo S, Indersie E, Jain BP, Trézéguet V, Gontier E, Lamoureux F, Guettier C, Mussini C, Hagedorn M, Armengol C, Grosset CF

Open source

DOI: 10.1186/s12943-025-02474-9
Published: 2026 Feb 23
Container: Molecular cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12943-025-02474-9,
  title = {EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.},
  author = {Khoubai FZ and Calovoulos A and Guillorit H and Carrillo-Reixach J and Del Rio-Alvarez A and Klein P and Coma MS and Avignon C and Rousseau B and Mora Charrot L and Fedou S and Dupuy JW and Royo L and Domingo-Sàbat M and Thézé N and Siegfried G and Khatib AM and Cairo S and Indersie E and Jain BP and Trézéguet V and Gontier E and Lamoureux F and Guettier C and Mussini C and Hagedorn M and Armengol C and Grosset CF},
  year = {2026},
  journal = {Molecular cancer},
  doi = {10.1186/s12943-025-02474-9},
  url = {https://doi.org/10.1186/s12943-025-02474-9}
}

RIS

TY  - JOUR
TI  - EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.
AU  - Khoubai FZ
AU  - Calovoulos A
AU  - Guillorit H
AU  - Carrillo-Reixach J
AU  - Del Rio-Alvarez A
AU  - Klein P
AU  - Coma MS
AU  - Avignon C
AU  - Rousseau B
AU  - Mora Charrot L
AU  - Fedou S
AU  - Dupuy JW
AU  - Royo L
AU  - Domingo-Sàbat M
AU  - Thézé N
AU  - Siegfried G
AU  - Khatib AM
AU  - Cairo S
AU  - Indersie E
AU  - Jain BP
AU  - Trézéguet V
AU  - Gontier E
AU  - Lamoureux F
AU  - Guettier C
AU  - Mussini C
AU  - Hagedorn M
AU  - Armengol C
AU  - Grosset CF
PY  - 2026
JO  - Molecular cancer
DO  - 10.1186/s12943-025-02474-9
UR  - https://doi.org/10.1186/s12943-025-02474-9
ER  -

APA

FZ, K., A, C., H, G., J, C., A, D. R., P, K., MS, C., C, A., B, R., L, M. C., S, F., JW, D., L, R., M, D., N, T., G, S., AM, K., S, C., E, I., BP, J., V, T., E, G., F, L., C, G., C, M., M, H., C, A., & CF, G. (2026). EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.. Molecular cancer. https://doi.org/10.1186/s12943-025-02474-9

Source records

pubmed · retrieved 2026-09-26T21:47:55.860Z